Immunotherapy with immune checkpoint inhibitors (ICI) that disrupt PD-1/PD-L1 interaction has proven highly effective in different tumor types (1), and different drugs have been approved so far by regulatory agencies for the treatment of advanced or metastatic urothelial carcinoma (UC) (2, 3). Here, CD274 is linked to neoplasm.